Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07438782 | First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors | PHASE1 | RECRUITING | 97 | — | — | Mar 23, 2026 | Feb 6, 2029 | May 27, 2026 | 8 | United States, Canada +1 |
ORR is defined as the proportion of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).
| Arm | Type | Description |
|---|---|---|
| Part 1a: GSK5533524 Dose Escalation & Backfill | EXPERIMENTAL | - |
| Part 1b: GSK5533524 Dose Expansion | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| GSK5533524 | DRUG | GSK5533524 will be administered. |
Inclusion Criteria: * Is at least 18 years of age or the legal age of consent * Has histologically or cytologically confirmed advanced/metastatic solid tumor that is refractory to standard therapy, for which no standard treatment is available, or who is intolerant to established standard of care th...